[{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"1214d7da-84ed-4b32-b0d2-16d88418f5bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06821048","created_at":"2025-02-25T15:46:38.357Z","updated_at":"2025-02-25T15:46:38.357Z","phase":"Phase 1","brief_title":"Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT06821048","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/24/2024","start_date":" 07/24/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-11"},{"id":"345523f2-eb95-47c4-aa63-da74c79fb6fc","acronym":"EVEREST-1","url":"https://clinicaltrials.gov/study/NCT05736731","created_at":"2023-02-21T15:01:17.869Z","updated_at":"2024-07-02T16:35:10.811Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT05736731 - EVEREST-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • HLA-A*02","tags":["HLA-A • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e A2B530"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-04-09"},{"id":"207f3b6a-911f-40e1-af15-23413b54bd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013111","created_at":"2023-08-28T14:08:22.937Z","updated_at":"2024-07-02T16:35:18.323Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors","source_id_and_acronym":"NCT06013111","lead_sponsor":"China Medical University, China","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CEA-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-02-21"},{"id":"ec924f14-828b-407b-8c51-af2c2883b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415475","created_at":"2023-11-14T16:14:28.256Z","updated_at":"2024-07-02T16:35:24.610Z","phase":"Phase 1","brief_title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05415475","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2024-01-04"},{"id":"9b7d28f1-9100-4935-af40-c1881d67e712","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010862","created_at":"2023-08-25T15:08:21.013Z","updated_at":"2024-07-02T16:35:29.975Z","phase":"Phase 1","brief_title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT06010862","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CEACAM5 positive","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-11-08"},{"id":"435ca39e-0679-4ca6-8e02-440b79b5541f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043466","created_at":"2023-09-21T15:10:27.528Z","updated_at":"2024-07-02T16:35:36.621Z","phase":"Phase 1","brief_title":"A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT06043466","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive","tags":["PD-L1 • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-09-21"},{"id":"57ba0d45-7caa-46e6-b460-70042994b802","acronym":"","url":"https://clinicaltrials.gov/study/NCT04348643","created_at":"2021-01-18T21:02:17.249Z","updated_at":"2024-07-02T16:35:50.385Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer","source_id_and_acronym":"NCT04348643","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":" | ","alterations":" CEACAM5 positive","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-04-18"},{"id":"cf042111-c026-42d8-bfbb-bbf21966b009","acronym":"","url":"https://clinicaltrials.gov/study/NCT03682744","created_at":"2021-01-18T18:03:27.452Z","updated_at":"2024-07-02T16:36:13.862Z","phase":"Phase 1","brief_title":"CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)","source_id_and_acronym":"NCT03682744","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2022-04-06"},{"id":"93f87e57-9718-4f29-b02f-982fc7f27fd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04037241","created_at":"2021-01-18T19:48:33.373Z","updated_at":"2024-07-02T16:36:14.266Z","phase":"Phase 2b","brief_title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer \u0026 Liver Metastases","source_id_and_acronym":"NCT04037241","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-04-01"},{"id":"6057d5a5-8252-4e03-8807-9ee477a97a89","acronym":"HITM-SURE","url":"https://clinicaltrials.gov/study/NCT02850536","created_at":"2021-01-18T13:59:34.702Z","updated_at":"2024-07-02T16:36:22.633Z","phase":"Phase 1","brief_title":"CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer","source_id_and_acronym":"NCT02850536 - HITM-SURE","lead_sponsor":"Roger Williams Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 02/01/2017","start_date":" 02/01/2017","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 09/17/2021","study_completion_date":" 09/17/2021","last_update_posted":"2021-10-21"},{"id":"afd5a8c4-3496-4ed3-a4ba-c4c144e184fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00673829","created_at":"2021-01-18T02:31:03.825Z","updated_at":"2024-07-02T16:37:31.244Z","phase":"Phase 1a/1b","brief_title":"Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer","source_id_and_acronym":"NCT00673829","lead_sponsor":"Roger Williams Medical Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Suspended","enrollment":" Enrollment 26","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-06-17"}]